Company Overview and News
June marks the eighth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $676.96.
SOJA ETP.PRC GIS XOM IDCC EPR.PRG O.PRF SKT LTC OPRF BPL SEP COP MIC CINF AAPL CAH EMR BBT SO TLP WLK O MSB OZRK CMI ETP SPG.PRJ HP ORI SPG WPC ADM
We are maintaining our STRONG BUY recommendation and we believe that as CIO’s dividend becomes safer (payout ratio under 100%) and the valuation gap should tighten.
KIM.PRI STAG.PRB STAG.PRC SKT KRG KIM.PRM KIM.PRL KIM.PRK KIM.PRJ BRX STAG.PRBCL CIO KIM STAG STAG.PRA
Between the four REIT team members, we met with over 50 REIT management teams at the June REITWeek conference.
KRC.PRG BPY KRC.PRH DCT KRC BXP TCO KRG UDR LSI TRNO EQR MAC JCAP.PRB AVB REG.PRG REG.PRF VNO EQIX TCO.PRK TCO.PRJ FR FRT JBGS RVI JCAP SPG QTS WPG PEI REG DLR.PRH DLR.PRG DLR.PRJ DLR.PRI SKT CXP EXR CONE COR ESS GGP EGP DDR MNR ROIC UE RPAI PLD SPG.PRJ KRLP OFC IRT BXP.PRB REXR DLR LPT DLR.PRC WRI DLR.PRF ESRT
The effects of Toys "R" Us closings on real-estate investment trusts (REITs) — the landlords of retail — will be larger than expected. Toys 'R' Us closings are not normal vacancies: these are some of the largest spaces on average by square foot in retail shopping centers and malls.
SPG.PRJ SKT SPG
SKT is trading at a significant discount to my estimated value of their net assets per share.
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG IRET.PR DUKH GD IRET.PRC TRV IRET.PRB GPT.PRB MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA GPT.PRA INTC TD IBM IRET.PRCL RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
This is the seventh month I have officially tracked the taxable account's dividend income, and it was slightly below expectations with a total of $1,642.46 of dividends received.
SOJA ETP.PRC GIS EBGUF XOM IDCC EPR.PRG O.PRF SKT LTC ENB OPRF BPL SEP COP MIC CINF AAPL CAH EMR EEP SO TLP WLK O MSB CMI WLKP ENB ETP SPG.PRJ HP PEP ORI SPG WPC ADM
Which dividend stocks are currently on my watch-list and what looks attractive for a new position.
ETP.PRC PG TWX SKT EPD ENB STWD.WI KO AGNC NRZ NLY NLY.PRA NLY.PRECL TWC NLY.PRD NLY.PRE NLY.PRC ENB NLY.PRF ETP BP NLY.PRG T STWD OHI
Since the above monster isn’t occupying retail space, we can assume that humans will continue to leave their homes to shop.
REG KIM.PRI SKT NYMTO TCO KIM.PRM KIM.PRL KIM.PRK NYMTP KIM.PRJ SFM GGP FRT.PRC KIM WRI.PRD REG.PRG REG.PRF TCO.PRK TCO.PRJ GGP.PRA FRT SPG.PRJ NYMT SPG WRI
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to SKT / Tanger Factory Outlet Centers, Inc. on message board site Silicon Investor.
as of ET